Name: Here's everything we know about the unapproved antibody drug Trump took to combat coronavirus
Brand: cnbc.com
SKU: cnbc-com-959
Availability: OnlineOnly

critic

Here's everything we know about the unapproved antibody drug Trump took to combat coronavirus

preview

Key PointsUsing Regeneron cocktail to treat Trump was a wholly appropriate call: Dr. GottliebFormer Food and Drug Administration commissioner Dr. Scott Gottlieb told CNBC on Friday he believes the White House carefully considered all of its treatment options before it President the experimental coronavirus antibody cocktail from&nbsp;.&nbsp;"This was a wholly appropriate decision to give him active therapy, and then it just became a choice of which therapy," Gottlieb said on &nbsp;prior to Trump to Walter Reed Medical Center "out of an abundance of caution" following his coronavirus diagnosis.&nbsp;"I wouldn't infer anything from the fact they chose the Regeneron product over another product&nbsp;— other than they probably had confidence looking at the data on the Regeneron product that it seemed to be the most effective of the products, given what they knew," added Gottlieb, who led the regulatory agency under Trump .&nbsp;Not everyone in the medical community agrees with Gottlieb about the decision to give Trump an experimental treatment. Some shared concerns about the preferential treatment provided to the president, as the drug has not been approved by federal regulators, and others pointed to the limited available data.&nbsp;On Twitter, as one doctor commented, "V.I.P. medicine doesn't mean better medicine when there is no data."Regeneron confirmed it provided a single, 8-gram dose of its REGN-COV2 treatment for use by the president, whose was announced just before 1 a.m. ET Friday. Regeneron's antibody drug is still experimental and has not received emergency use approval from the FDA, but it was provided in response to a compassionate use request.&nbsp;CNBC's on Friday reported that a "limited number of patients" had also received the drug on that basis after speaking with Regeneron's chief scientific officer, Dr. George Yancopoulos.&nbsp;On Tuesday, Regeneron said its REGN-COV2 treatment &nbsp;in non-hospitalized patients who have mild to moderate Covid-19. That was based on results for the first 275 trial patients. At the time, the company indicated it the early results with regulatory agencies, including the FDA.&nbsp;Regeneron is not the only company developing antibody drugs; and &nbsp;also are testing monoclonal antibodies, which experts have viewed as a .Regeneron's REGN-COV2 is an experimental shot of lab-generated antibodies that mimics how the body would mount a reaction to a foreign invader. The goal is to boost the immune system's defenses, rather than to wait on human biology to do its job.&nbsp;In a memo provided Friday by the White House, Trump's physician, Dr. Sean Conley, said the president was given Regeneron's antibody cocktail Conley also wrote that Trump "remains fatigued but in good spirits."&nbsp;Trump also has a , NBC News reported Friday afternoon, citing three people familiar with his condition.&nbsp;The White House did not immediately respond to CNBC's request for comment on the decision to give Trump the antibody drug.Gottlieb said he thought that if Trump were going to receive any early treatments for Covid-19, it to be&nbsp;' remdesivir. The antiviral drug has received emergency approval from the FDA, but for hospitalized coronavirus patients .&nbsp;"I would have thought they would use remdesivir because there's more data around that drug at this point and we are seeing that drug be used earlier and earlier in the course of the disease," Gottlieb said, adding that he is "optimistic" about Regeneron's drug, but it's still very early."You might get a lot of benefit but you just don't know," he said.&nbsp;However, Gottlieb pushed back on any suggestion that Trump receiving Regeneron's treatment should be cause for alarm. He said virtually any other American, at this point of their coronavirus diagnosis, would just be monitored by medical professionals, hoping symptoms don't intensify."For a president of the United States, if you have available therapy, I think you deliver it, especially if you understand the safety profile of these products and you believe they are otherwise going to be safe and aren't going to worsen his condition," Gottlieb said.&nbsp;Some doctors are skeptical, however, of the decision to treat Trump with the antibody drug. "It is bad science, bad medicine and bad ethics to give unproven things to powerful people," wrote Dr. Vinay Prasad in a Twitter post. Prasad is an associate professor of medicine and practicing hematologist-oncologist at University of California San Francisco.&nbsp;"I will say that in no case have I heard of a patient, especially of the importance of the president, getting an experimental infusion of an antibody cocktail," added Seattle-based pulmonologist Dr. Vin Gupta , who also pressed for more information from the White House.In addition to Regeneron's antibody cocktail, the president is also taking zinc, Vitamin D and the histamine-blocker famotidine.&nbsp;The famotidine treatment was "speculative" at this point, even though there are studies looking at whether it could be beneficial on coronavirus patients, Gottlieb said."There are studies that suggest if you're low on Vitamin D, Vitamin D supplementation can be beneficial, but you'd want to be on Vitamin D prior to getting sick," he added. "I don't think any of those drugs are problematic or could cause harm, I just don't know that they're going to provide a treatment effect in this setting."Regeneron reports positive results on initial data for Covid-19 antibody drugDisclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of&nbsp;Pfizer, genetic testing start-up&nbsp;Tempus and biotech company&nbsp;.&nbsp;Pfizer has a manufacturing agreement with Gilead for remdesivir. Gottlieb&nbsp;also serves as co-chair of&nbsp;′ and&nbsp;'s "Healthy Sail Panel."&nbsp;

Key PointsUsing Regeneron cocktail to treat Trump was a wholly appropriate call: Dr. GottliebFormer Food and Drug Administration commissioner Dr. Scott Gottlieb told CNBC on Friday he believes the White House carefully considered all of its treatment options before it President the experimental coronavirus antibody cocktail from&nbsp;.&nbsp;"This was a wholly appropriate decision to give him active therapy, and then it just became a choice of which therapy," Gottlieb said on &nbsp;prior to Trump to Walter Reed Medical Center "out of an abundance of caution" following his coronavirus...

Here's everything we know about the unapproved antibody drug Trump took to combat coronavirus

No article scores yet.

CRITIC REVIEWS

PUBLIC REVIEWS